title: [Combined radio-/chemotherapy of invasive bladder cancer].
abstract: In a prospective study, 19 patients with advanced transitional carcinoma of the bladder (stages T.3 and T.4) were treated by combined radiotherapy and chemotherapy. A total of 450 mg cis-platinum or 1.6 mg/kg body weight were given in four treatment periods with three-week intervals. At the same time, the total dose of 60 Gy was given to the tumour over two periods (telecobalt or high-energy photons). There were few systemic or toxic side effects. Recurrence-free survival during the next 36 months was 76%, which compares with a control group treated by irradiation only, who had a survival of 48%.
authors.forename: E
authors.initials: E
authors.lastname: Fritsch
authors.forename: G
authors.initials: G
authors.lastname: Jakse
authors.forename: H
authors.initials: H
authors.lastname: Frommhold
mesh_terms: D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011859:Radiography; D011882:Radiotherapy, High-Energy; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*
chemical_list: D002945:Cisplatin
vernacular_title: Kombinierte Radio-/Chemotherapie des invasiven Harnblasenkarzinoms.